<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37243185</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1099</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15051099</ELocationID><Abstract><AbstractText>The rapid mutation and spread of SARS-CoV-2 variants recently, especially through the emerging variants Omicron BA5, BF7, XBB and BQ1, necessitate the development of universal vaccines to provide broad spectrum protection against variants. For the SARS-CoV-2 universal recombinant protein vaccines, an effective approach is necessary to design broad-spectrum antigens and combine them with novel adjuvants that can induce high immunogenicity. In this study, we designed a novel targeted retinoic acid-inducible gene-I (RIG-I) receptor 5'triphosphate double strain RNA (5'PPP dsRNA)-based vaccine adjuvant (named AT149) and combined it with the SARS-CoV-2 Delta and Omicron chimeric RBD-dimer recombinant protein (D-O RBD) to immunize mice. The results showed that AT149 activated the P65 NF-κB signaling pathway, which subsequently activated the interferon signal pathway by targeting the RIG-I receptor. The D-O RBD + AT149 and D-O RBD + aluminum hydroxide adjuvant (Al) + AT149 groups showed elevated levels of neutralizing antibodies against the authentic Delta variant, and Omicron subvariants, BA1, BA5, and BF7, pseudovirus BQ1.1, and XBB compared with D-O RBD + Al and D-O RBD + Al + CpG7909/Poly (I:C) groups at 14 d after the second immunization, respectively. In addition, D-O RBD + AT149 and D-O RBD + Al + AT149 groups presented higher levels of the T-cell-secreted IFN-γ immune response. Overall, we designed a novel targeted RIG-I receptor 5'PPP dsRNA-based vaccine adjuvant to significantly improve the immunogenicity and broad spectrum of the SARS-CoV-2 recombinant protein vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shanghai JunTuo Biotechnology Co., Ltd., Shanghai 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuanxuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd., Beijning 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Feiran</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9460-9949</Identifier><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089582">Adjuvants, Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>NU43IAG5BC</RegistryNumber><NameOfSubstance UI="C005692">triphosphoric acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000017">ABO Blood-Group System</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089582" MajorTopicYN="N">Adjuvants, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000017" MajorTopicYN="N">ABO Blood-Group System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">recombinant protein vaccine</Keyword><Keyword MajorTopicYN="N">retinoic acid-inducible gene-I (RIG-I) receptor</Keyword><Keyword MajorTopicYN="N">vaccine adjuvant</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37243185</ArticleId><ArticleId IdType="pmc">PMC10220529</ArticleId><ArticleId IdType="doi">10.3390/v15051099</ArticleId><ArticleId IdType="pii">v15051099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao F., Zai X., Zhang Z., Xu J., Chen W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ Vaccines. 2022;7:167. doi: 10.1038/s41541-022-00597-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00597-4</ArticleId><ArticleId IdType="pmc">PMC9761649</ArticleId><ArticleId IdType="pubmed">36535982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., He Q., Yang J., Lu S., Mao Q., Gao F., Bian L., Zhang J., An C., Liu J., et al. B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but LessViral Shedding than That of the Ancestral Strain in YoungNonhuman Primates. Microbiol. Spectr. 2022;10:e02263-22. doi: 10.1128/spectrum.02263-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02263-22</ArticleId><ArticleId IdType="pmc">PMC9603226</ArticleId><ArticleId IdType="pubmed">36069561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Wang Q., Liu M., Bian L., Liu J., Gao F., Mao Q., Wang Z., Wu X., Xu M., et al. The next major emergent infectious disease: Reflections on vaccine emergency development strategies. Expert Rev. Vaccines. 2022;21:471–481. doi: 10.1080/14760584.2022.2027240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2027240</ArticleId><ArticleId IdType="pubmed">35080441</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Q., Luo W., Mallajosyula V., Bo Y., Guo J., Xie J., Sun M., Verma R., Li C., Constantz C.M., et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 2023;22:380–390. doi: 10.1038/s41563-022-01464-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-022-01464-2</ArticleId><ArticleId IdType="pmc">PMC9981462</ArticleId><ArticleId IdType="pubmed">36717665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B., SArunachalam P., O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discovry. 2021;20:454–475. doi: 10.1038/s41573-021-00163-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00163-y</ArticleId><ArticleId IdType="pmc">PMC8023785</ArticleId><ArticleId IdType="pubmed">33824489</ArticleId></ArticleIdList></Reference><Reference><Citation>Seenappa L.M., Jakubowski A., Steinbuck M.P., Palmer E., Haqq C.M., Carter C., Fontenot J., Villinger F., McNeil L.K., DeMuth P.C. Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. NPJ Vaccines. 2022;7:128. doi: 10.1038/s41541-022-00560-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00560-3</ArticleId><ArticleId IdType="pmc">PMC9616425</ArticleId><ArticleId IdType="pubmed">36307453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanishi E., Borriello F., O’Meara T.R., McGrath M.E., Saito Y., Haupt R.E., Seo H.S., van Haren S.D., Cavazzoni C.B., Brook B., et al. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Sci. Transl. Med. 2021;14:eabj5305. doi: 10.1126/scitranslmed.abj5305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj5305</ArticleId><ArticleId IdType="pmc">PMC10176044</ArticleId><ArticleId IdType="pubmed">34783582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni R.R., Rasheed M.A., Bhaumik S.K., Ranjan P., Cao W., Davis C., Marisetti K., Thomas S., Gangappa S., Sambhara S., et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J. Virol. 2014;88:13990–14001. doi: 10.1128/JVI.02273-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02273-14</ArticleId><ArticleId IdType="pmc">PMC4249139</ArticleId><ArticleId IdType="pubmed">25253340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., Israelow B., Lucas C., Vogels C.B., Gomez-Calvo M.L., Fedorova O., Breban M.I., Menasche B.L., Dong H., Linehan M. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. J. Exp. Med. 2022;219:e20211818. doi: 10.1084/jem.20211818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211818</ArticleId><ArticleId IdType="pmc">PMC8590200</ArticleId><ArticleId IdType="pubmed">34757384</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., An C., Bai Y., Li K., Liu J., Wang Q., He Q., Song Z., Zhang J., Song L., et al. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine. Viruses. 2022;14:1854. doi: 10.3390/v14091854.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091854</ArticleId><ArticleId IdType="pmc">PMC9504790</ArticleId><ArticleId IdType="pubmed">36146661</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z., Wang Q., Bian L., An C., Cui B., Mao Q., Wu X., He Q., Bai Y., Liu J., et al. A Short 5’triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I. Viruses. 2022;14:2451. doi: 10.3390/v14112451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112451</ArticleId><ArticleId IdType="pmc">PMC9694983</ArticleId><ArticleId IdType="pubmed">36366549</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K., Gao P., Liu S., Lu S., Lei W., Zheng T., Liu X., Xie Y., Zhao Z., Guo S., et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022;185:2265–2278.e2214. doi: 10.1016/j.cell.2022.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.029</ArticleId><ArticleId IdType="pmc">PMC9042943</ArticleId><ArticleId IdType="pubmed">35568034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Bai Y., Gao F., Liu M., He Q., Wu X., Mao Q., Xu M., Liang Z. Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice. Virol. J. 2022;19:86. doi: 10.1186/s12985-022-01818-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01818-x</ArticleId><ArticleId IdType="pmc">PMC9122244</ArticleId><ArticleId IdType="pubmed">35596222</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Mao Q., An C., Zhang J., Gao F., Bian L., Li C., Liang Z., Xu M., Wang J. Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infect. 2021;10:629–637. doi: 10.1080/22221751.2021.1902245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1902245</ArticleId><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Song Z., Yang J., He Q., Mao Q., Bai Y., Liu J., An C., Yan X., Cui B., et al. Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. Emerg. Microbes Infect. 2022;11:1145–1153. doi: 10.1080/22221751.2022.2059404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2059404</ArticleId><ArticleId IdType="pmc">PMC9037177</ArticleId><ArticleId IdType="pubmed">35343384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Liu D., He Q., Liu J., Mao Q., Liang Z. Research progress on circular RNA vaccines. Front. Immunol. 2023;13:1091797. doi: 10.3389/fimmu.2022.1091797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1091797</ArticleId><ArticleId IdType="pmc">PMC9878156</ArticleId><ArticleId IdType="pubmed">36713460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Lu L., Peng Z., Chen L.L., Meng X., Zhang C., Ip J.D., Chan W.M., Chu A.W., Chan K.H., et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect. 2022;11:277–283. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L., Yi Z., Shen Y., Lin L., Chen F., Xu Y., Wu Z., Tang H., Zhang X., Tian F., et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185:1728–1744.e1716. doi: 10.1016/j.cell.2022.03.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId><ArticleId IdType="pmc">PMC8971115</ArticleId><ArticleId IdType="pubmed">35460644</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoryan L., Lee A., Walls A.C., Lai L., Franco B., Arunachalam P.S., Feng Y., Luo W., Vanderheiden A., Floyd K., et al. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ Vaccines. 2022;7:55. doi: 10.1038/s41541-022-00472-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00472-2</ArticleId><ArticleId IdType="pmc">PMC9126867</ArticleId><ArticleId IdType="pubmed">35606518</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleebrahim-Dehkordi E., Molavi B., Mokhtari M., Deravi N., Fathi M., Fazel T., Mohebalizadeh M., Koochaki P., Shobeiri P., Hasanpour-Dehkordi A. T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transpl. Immunol. 2022;70:101495. doi: 10.1016/j.trim.2021.101495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trim.2021.101495</ArticleId><ArticleId IdType="pmc">PMC8579696</ArticleId><ArticleId IdType="pubmed">34774738</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens D.M., Taubenberger J.K., Fauci A.S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe. 2023;31:146–157. doi: 10.1016/j.chom.2022.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.11.016</ArticleId><ArticleId IdType="pmc">PMC9832587</ArticleId><ArticleId IdType="pubmed">36634620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>